Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

Sevindzh F Evdokimova; Anna L Kornietskaya; Larisa V Bolotina; Iliya V Kolobayev; Alexander A Fedenko; Andrey D Kaprin

doi:10.3389/fonc.2024.1494669

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

Front Oncol. 2024 Dec 6:14:1494669. doi: 10.3389/fonc.2024.1494669. eCollection 2024.

Authors

Sevindzh F Evdokimova¹, Anna L Kornietskaya¹, Larisa V Bolotina¹, Iliya V Kolobayev¹, Alexander A Fedenko¹, Andrey D Kaprin^{1

2}

Affiliations

¹ P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
² Peoples' Friendship University of Russia, Moscow, Russia.

Abstract

The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.

Keywords: case report; conversion surgery; gastric cancer (GC); gastroesophageal junction (GEJ); immunotherapy; pembrolizumab.

Publication types

Case Reports

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.